[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,782,539
  • Shares Outstanding, K 58,127
  • Annual Sales, $ 718,950 K
  • Annual Income, $ -38,550 K
  • EBIT $ -31 M
  • EBITDA $ 59 M
  • 60-Month Beta 0.56
  • Price/Sales 3.79
  • Price/Cash Flow 12.42
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 47.14% (+0.76%)
  • Historical Volatility 42.57%
  • IV Percentile 42%
  • IV Rank 52.50%
  • IV High 66.99% on 09/26/25
  • IV Low 25.20% on 08/12/25
  • Expected Move (DTE 8) 1.66 (3.51%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 23
  • Put/Call OI Ratio 3.65
  • Today's Open Interest 2,118
  • Open Int (30-Day) 1,961
  • Expected Range 45.60 to 48.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.66
  • Number of Estimates 2
  • High Estimate $0.85
  • Low Estimate $0.46
  • Prior Year $0.46
  • Growth Rate Est. (year over year) +43.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.63 +10.39%
on 08/04/26
52.50 -10.38%
on 08/03/26
-0.30 (-0.63%)
since 07/13/26
3-Month
42.45 +10.84%
on 06/16/26
52.50 -10.38%
on 08/03/26
-4.31 (-8.39%)
since 05/13/26
52-Week
41.76 +12.67%
on 08/14/25
59.68 -21.16%
on 02/25/26
+4.41 (+10.35%)
since 08/13/25

Most Recent Stories

More News
Are BOW, ATKR, SUPN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ATKR : 93.82 (+0.01%)
SUPN : 47.34 (-1.11%)
BOW : 33.53 (-0.18%)
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals...

INDV : 38.48 (-0.65%)
SUPN : 47.34 (-1.11%)
Stocks Settle Sharply Higher as Middle East Tensions Ease

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.78%. September E-mini...

ALK : 47.45 (+0.17%)
GOOGL : 346.31 (+0.81%)
MPC : 355.41 (+2.06%)
CRCL : 74.74 (+4.85%)
TRI : 106.09 (+3.39%)
OXY : 57.69 (-1.47%)
TSLA : 338.92 (+3.48%)
GLW : 159.20 (-4.92%)
FANG : 198.64 (-0.55%)
FERG : 247.79 (+1.06%)
SPY : 777.83 (+0.69%)
GME : 18.67 (+0.70%)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

NEW YORK , Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

SUPN : 47.34 (-1.11%)
Are SUPN, ITGR, ATKR, LNTH Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ATKR : 93.82 (+0.01%)
ITGR : 125.01 (-0.06%)
LNTH : 100.83 (+0.10%)
SUPN : 47.34 (-1.11%)
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE , Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Supernus (Nasdaq: SUPN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction...

SUPN : 47.34 (-1.11%)
Stocks Rally on Easing Geopolitical Risks and US Economic Strength

The S&P 500 Index ($SPX ) (SPY ) today is up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.081%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.40%. September E-mini S&P futures...

ALK : 47.45 (+0.17%)
GOOGL : 346.31 (+0.81%)
UAL : 126.31 (+0.95%)
ATKR : 93.82 (+0.01%)
DDOG : 252.36 (+4.75%)
SUPN : 47.34 (-1.11%)
CRCL : 74.74 (+4.85%)
$IUXX : 30,133.38 (+1.31%)
FICO : 1,110.18 (+6.32%)
ZNU26 : 108-290 (+0.33%)
MSFT : 498.10 (+1.15%)
TSLA : 338.92 (+3.48%)
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior...

SUPN : 47.34 (-1.11%)
Stocks Supported by Easing Middle East Tensions

The S&P 500 Index ($SPX ) (SPY ) today is up +0.84%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.47%. September E-mini S&P futures...

ALK : 47.45 (+0.17%)
ADI : 380.92 (-0.91%)
CRCL : 74.74 (+4.85%)
SLB : 52.07 (-1.03%)
OXY : 57.69 (-1.47%)
FANG : 198.64 (-0.55%)
FERG : 247.79 (+1.06%)
STX : 919.38 (+4.69%)
WDC : 486.47 (+7.13%)
AMD : 486.44 (+0.73%)
SPY : 777.83 (+0.69%)
GME : 18.67 (+0.70%)
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%

SUPN : 47.34 (-1.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 50.10
2nd Resistance Point 49.01
1st Resistance Point 48.44
Last Price 47.34
1st Support Level 46.78
2nd Support Level 45.69
3rd Support Level 45.12

See More

52-Week High 59.68
Fibonacci 61.8% 52.83
Fibonacci 50% 50.72
Fibonacci 38.2% 48.61
Last Price 47.34
52-Week Low 41.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.